Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
Name:
37196483.pdf
Size:
2.213Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Hernando, J.Roca-Herrera, M.
García-Álvarez, A.
Raymond, E.
Ruszniewski, P.
Kulke, M. H.
Grande, E.
García-Carbonero, R.
Castellano, D.
Salazar, R.
Ibrahim, T.
Teule, A.
Alonso, V.
Fazio, N.
Valle, Juan W
Tafuto, S.
Carmona, A.
Navarro, V.
Capdevila, J.
Affiliation
Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.Issue Date
2023
Metadata
Show full item recordAbstract
Purpose: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like neuroendocrine tumours (NET). In the present study, we combine the differential toxicities by sex in five published clinical trials with multikinase inhibitors (MKI) in gastroenteropancreatic (GEP) NET. Methods: We performed a pooled univariate analysis of reported toxicity in patients treated in five phase 2 and phase 3 clinical trials with MKI in the GEP NET setting: sunitinib (SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT). Differential toxicities between male and female patients were evaluated considering relationship with study drug and different weights of each trial by random effect adjustment. Results: We found nine toxicities which were more frequent in female patients (leukopenia, alopecia, vomiting, headache, bleeding, nausea, dysgeusia, neutrophil count decreased and dry mouth) and two toxicities being more frequent in male patients (Anal Symptoms and Insomnia). Asthenia and diarrhoea were the only severe (Grade 3-4) toxicities more frequent in female patients. Conclusions: Sex-related differences in toxicity with the MKI treatment require targeted information and individualised management of patients with NET. Differential reporting of toxicity should be promoted when clinical trials are published.Citation
Hernando J, Roca-Herrera M, García-Álvarez A, Raymond E, Ruszniewski P, Kulke MH, et al. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours. European journal of cancer (Oxford, England : 1990). 2023 Apr 23;188:39-48. PubMed PMID: 37196483. Epub 2023/05/18. eng.Journal
European Journal of CancerDOI
10.1016/j.ejca.2023.04.013PubMed ID
37196483Additional Links
https://dx.doi.org/10.1016/j.ejca.2023.04.013Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2023.04.013